LUXEMBOURG VILLE, Luxembourg, May 17, 2016 /PRNewswire-iReach/ -- Advanced Biological Laboratories (ABL) S.A. today announced the signing of an exclusive worldwide license for the use and development of the intellectual property, compositions and related know-how with the French National Institute of Health and Medical Research (Inserm) subsidiary, Inserm Transfert SA, representing the research unit Inserm U1052/ CNRS UMR5286, "Centre de Recherche en Cancérologie de Lyon (CRCL)", Lyon, France.
The ELISA test developed by Dr. Marie-Anne Petit and Prof. Christian Trépo is an anti-E1E2A, B/D32.10-like antibodies detection test indicated in the management of HCV infections.
"This unique anti-HCV E1E2 ELISA product allows the identification and monitoring of hepatitis C infected-patients even before the commencement of antiviral therapy with very efficient new drugs. Similar to the hepatitis C RNA viral load, there exists a relationship between anti-E1E2 titers in pretreatment serum and HCV RNA kinetic profiles during therapy," said Dr. M.-A. Petit.
"Our discovered Anti-E1/E2-based ELISA assay allows the exploration of treatment options prior to therapy initiation. Treatment response prediction of hepatitis C infected-patients taking anti-HCV drugs, including direct antiviral agents (DAA), should lead to optimal and cost-effective personalized patient management," said Prof. Trépo.
"The distinctive anti-E1/E2 ELISA test developed by Dr. M.-A. Petit, and the other diagnostic and therapeutic applications to be developed, now form part of the new segment of products that the ABL group is commercializing together with its DeepChek(r) SingleRound HCV and HIV genotyping reagents. It completes the portfolio of tests for viral applications," said Dr. Chalom B. Sayada, CEO of ABL. "These products will be produced and commercialized by our affiliate in France. These tests can be used at several time points during the monitoring of HCV-infected patients. This technology shall also pave the way for the development of innovative therapeutics for curing HCV infection," added Dr. Sayada.
Financial details of this licensing agreements were not disclosed.
About ABL
Advanced Biological Laboratories (ABL), S.A., is a Medical Data Technology company founded in 2000 as a spin-off from CRP-Santé Luxembourg. ABL took control of TherapyEdge, Inc. in 2004 and in 2013 acquired the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL, respectively. ABL has a comprehensive suite of healthcare management products, including TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, VisibleChek®, HepatiC® and the DPM which are used for data and patient management, monitoring and personalized reporting applications. In 2012, some of ABL's products also received CE-marking for IVD use. ABL's products, ViroScore® Suite and DeepChek®, are for research use only in the United States, and the upcoming data processing module is a FDA registered class I medical device. ABL's products offer infectious disease clinicians and virology laboratories optimal and efficient IT solutions for sequencing, clinical genotyping and drug resistance analysis, including powerful fully integrated databases and analysis systems that combe standard and high-throughput Next Generation Sequencing data. ABL's DeepChek® SingleRound HIV and Hepatitis C Virus (HCV) Genotyping and Sequencing assays are the first two in its virology reagents portfolio. These are currently available for Research Use Only.
The ELISA test developed by Dr. Marie-Anne Petit and Prof. Christian Trépo is an anti-E1E2A, B/D32.10-like antibodies detection test indicated in the management of HCV infections.
"This unique anti-HCV E1E2 ELISA product allows the identification and monitoring of hepatitis C infected-patients even before the commencement of antiviral therapy with very efficient new drugs. Similar to the hepatitis C RNA viral load, there exists a relationship between anti-E1E2 titers in pretreatment serum and HCV RNA kinetic profiles during therapy," said Dr. M.-A. Petit.
"Our discovered Anti-E1/E2-based ELISA assay allows the exploration of treatment options prior to therapy initiation. Treatment response prediction of hepatitis C infected-patients taking anti-HCV drugs, including direct antiviral agents (DAA), should lead to optimal and cost-effective personalized patient management," said Prof. Trépo.
"The distinctive anti-E1/E2 ELISA test developed by Dr. M.-A. Petit, and the other diagnostic and therapeutic applications to be developed, now form part of the new segment of products that the ABL group is commercializing together with its DeepChek(r) SingleRound HCV and HIV genotyping reagents. It completes the portfolio of tests for viral applications," said Dr. Chalom B. Sayada, CEO of ABL. "These products will be produced and commercialized by our affiliate in France. These tests can be used at several time points during the monitoring of HCV-infected patients. This technology shall also pave the way for the development of innovative therapeutics for curing HCV infection," added Dr. Sayada.
Financial details of this licensing agreements were not disclosed.
About ABL
Advanced Biological Laboratories (ABL), S.A., is a Medical Data Technology company founded in 2000 as a spin-off from CRP-Santé Luxembourg. ABL took control of TherapyEdge, Inc. in 2004 and in 2013 acquired the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL, respectively. ABL has a comprehensive suite of healthcare management products, including TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, VisibleChek®, HepatiC® and the DPM which are used for data and patient management, monitoring and personalized reporting applications. In 2012, some of ABL's products also received CE-marking for IVD use. ABL's products, ViroScore® Suite and DeepChek®, are for research use only in the United States, and the upcoming data processing module is a FDA registered class I medical device. ABL's products offer infectious disease clinicians and virology laboratories optimal and efficient IT solutions for sequencing, clinical genotyping and drug resistance analysis, including powerful fully integrated databases and analysis systems that combe standard and high-throughput Next Generation Sequencing data. ABL's DeepChek® SingleRound HIV and Hepatitis C Virus (HCV) Genotyping and Sequencing assays are the first two in its virology reagents portfolio. These are currently available for Research Use Only.
